629P Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study - R. de Wit, C. Wülfing, D. Castellano Gauna, G. Kramer, J.-C. Eymard, C. N. Sternberg, K. Fizazi, B. Tombal, A. Bamias, J. Carles, R. Iacovelli, B. Melichar, Á. Sverrisdóttir, C. Theodore, S. Feyerabend - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Elsevier, Annals of Oncology, (31), p. S519-S520, 2020

DOI: 10.1016/j.annonc.2020.08.888

Links

Tools

Export citation

Search in Google Scholar

629P Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study

Journal article published in 2020 by R. de Wit, C. Wülfing, D. Castellano Gauna, G. Kramer, J.-C. Eymard, C. N. Sternberg, K. Fizazi, B. Tombal, A. Bamias, J. Carles, R. Iacovelli, B. Melichar, Á. Sverrisdóttir, C. Theodore, S. Feyerabend and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO